Quick Facts: Therapeutic Domains

• Adult Plaque Psoriasis: Intended for the management of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• Adult Psoriatic Arthritis: Utilized for the treatment of active psoriatic arthritis in adults.
• Adult Crohn’s Disease: Indicated for use in adults with moderately to severely active Crohn's disease.
• Adult Ulcerative Colitis: Employed for the management of moderately to severely active ulcerative colitis in adults.

---

What Skyrizi Treats: Main Uses and Benefits

Skyrizi (risankizumab-rzaa) is an approved therapy used to address several chronic, immune-mediated inflammatory conditions in adult patients. Its primary role is to provide relief from symptoms associated with these conditions.

The medication is indicated for the treatment of moderate-to-severe plaque psoriasis, an inflammatory skin condition that can benefit from systemic treatment. In addition, it is used in the therapeutic management of active psoriatic arthritis. For individuals living with psoriatic arthritis, this therapy may help manage joint-related symptoms and contribute to an improvement in physical function.

Skyrizi is also approved to treat two inflammatory bowel diseases: moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis. Treatment in these patient populations is intended to support the reduction of disease activity and promote clinical improvement in the digestive tract. These therapeutic uses are established through clinical evaluation of the medication's effect on these conditions.

Skyrizi (risankizumab-rzaa) is officially approved for use only in adults for its indicated conditions. The safety and effectiveness of the medicine in children and adolescents (pediatric patients) have not been established according to regulatory documents.

Populations Who Must Not Use Skyrizi

Classification	Condition or Population
Absolute Contraindication	History of serious hypersensitivity reaction (including anaphylaxis) to risankizumab-rzaa or any of its inactive ingredients.
Prohibited Use	Presence of a clinically important active infection, including active tuberculosis (TB), until the infection resolves or is adequately treated.

Restricted or Conditional Use

Before starting Skyrizi, patients must be evaluated for latent TB infection and receive treatment if needed. Patients must also avoid receiving live vaccines during treatment. For pregnant women, use is generally not recommended due to limited data, and women of childbearing potential are advised to use effective contraception during and for a specified period after treatment. For those with Crohn's disease or ulcerative colitis, liver enzymes and bilirubin levels must be monitored before and during the initial phase of treatment.

Interactions with Other Medicines and Products

Skyrizi (risankizumab-rzaa) has a targeted interaction profile primarily due to its structure as a large protein biologic medicine, which is not metabolized by the body’s main drug-processing enzyme systems.

Interaction Type	Official Regulatory Statement
Live Vaccines	Co-administration is formally prohibited (contraindicated). Medications affecting the immune system may increase the risk of infection following live vaccine administration.
Timing Requirements	Age-appropriate immunizations should be completed prior to initiating treatment. Live vaccines should be avoided during treatment and, in some regions, for at least 21 weeks after stopping therapy.
Metabolic Interactions	No clinically relevant pharmacokinetic interactions are expected with co-administered medicines that are substrates, inhibitors, or inducers of Cytochrome P450 (CYP) enzymes, as risankizumab is not cleared via these enzymes.
Unstudied Combinations	The safety and efficacy of combining Skyrizi with other immunosuppressants (including other biologics) or phototherapy have not been evaluated in clinical trials.
Excipient Note	For some European formulations, the excipient sorbitol is present, and its additive effect from concomitant products or dietary intake must be accounted for.

This interaction profile is defined by a significant pharmacodynamic restriction against live vaccines, alongside a low potential for traditional CYP-mediated drug interactions, a finding supported by official regulatory documentation.

Selective Neutralization of Interleukin-23 (IL-23)

Risankizumab-rzaa, the active component, operates as a high-affinity neutralizing antagonist by specifically binding to the p19 subunit of the Interleukin-23 (IL-23) cytokine. This physical blockade prevents the soluble IL-23 molecule from linking to its cognate receptor (IL-23R) on target immune cells. By targeting the p19 subunit, the mechanism maintains specificity to the IL-23 pathway and does not interact with the functionally distinct IL-12 pathway.

Downstream Suppression of the Th17 Axis

The neutralization of IL-23 interrupts the entire inflammatory signaling cascade known as the IL-23/Th17 axis. Since IL-23 is required for the proliferation and function of T helper 17 (Th17) cells, blocking its signal inhibits the downstream intracellular events (like STAT3 activation) required for Th17 cell function. This key molecular step leads to a reduction in the production and secretion of inflammatory mediators, primarily Interleukin-17A and Interleukin-22. This systemic downregulation of cytokine release represents the final measurable pharmacodynamic consequence of the drug's mechanism.

How Skyrizi is Used: Official Administration Guidelines

The usage of Skyrizi (risankizumab-rzaa) is governed by specific administration routes, dosing strengths, and schedules that vary according to the condition being managed. The therapy follows a standardized approach consisting of an initial higher-frequency phase and a long-term maintenance phase.

Administration Routes and Forms

Skyrizi is administered via two approved routes. Subcutaneous (SC) injection is the route for all maintenance therapy and the entire regimen for Plaque Psoriasis and Psoriatic Arthritis. The subcutaneous injection is typically provided in prefilled pens or syringes containing 150 mg or 75 mg strengths. The Intravenous (IV) infusion route is used exclusively for the initial induction phase of treatment for Crohn's Disease and Ulcerative Colitis.

Standard Dosing Schedules

Indication	Initial Dosing	Maintenance Frequency
Plaque Psoriasis, Psoriatic Arthritis	150 mg SC at Week 0 and Week 4	150 mg SC every 12 weeks
Crohn's Disease	600 mg IV at Week 0, 4, 8	180 mg or 360 mg SC every 8 weeks
Ulcerative Colitis	1,200 mg IV at Week 0, 4, 8	180 mg or 360 mg SC every 8 weeks

Procedural Context and Timing

For subcutaneous administration, the device must be allowed to reach room temperature before injection. Patients may self-inject after training, using the abdomen or thigh, and must avoid sites with compromised skin. The intravenous induction phase requires administration in a healthcare setting over a minimum duration: at least one hour for Crohn's Disease and at least two hours for Ulcerative Colitis. If a maintenance dose is missed, it should be administered as soon as possible, and the original schedule then resumed. No dose adjustments are generally required for older adults or patients with renal or hepatic impairment.

Research Evidence / Overview of Studies for Skyrizi

Evidence for Use in Plaque Psoriasis

Research examining risankizumab-rzaa (Skyrizi) was evaluated in large-scale, short-term Randomized Controlled Trials (RCTs) (Phase 3). These studies included adult patients, some of whom had already tried and not responded sufficiently to other systemic treatments or biologics. The trials were used in research exploring how symptoms change over time by measuring standardized outcomes like the Psoriasis Area and Severity Index (PASI) and the static Physician’s Global Assessment (sPGA), along with patient-reported outcomes describing perceived discomfort and quality of life.

Findings describe patterns observed in the studies where a greater frequency of participants met the measured endpoints for improvement in the severity and extent of their skin condition by the 16-week primary analysis point compared to the placebo groups. In active-comparator trials, the research examined measurements of disease activity that were examined against a comparator agent. Study findings were comparable across multiple independent short-term studies.

---

Evidence for Use in Psoriatic Arthritis

Research examining risankizumab-rzaa for active psoriatic arthritis was observed in studies involving adult patients. RCTs were applied in studies examining patient-reported experiences and objective measures related to joint and skin symptoms. These studies included individuals who had an inadequate response to traditional non-biologic and some biologic disease-modifying anti-rheumatic drugs.

The main outcomes related to physical discomfort that research examined were changes in joint counts using the ACR response criteria (ACR20, 50, and 70). Studies also monitored outcomes related to specific features of the condition, such as dactylitis (swollen digits) and enthesitis (inflammation where tendons meet bone). Findings indicate patterns related to a greater frequency of participants meeting the measured criteria related to joint activity and function compared to those receiving a placebo over the 24-week short-term period.

---

Long-Term Studies and What Is Still Uncertain

Following the initial short-term, placebo-controlled trials, long-term follow-up has primarily been studied in Open-Label Extension (OLE) trials. These OLE studies were used in research exploring how symptoms change over time for up to several years. The measured outcomes evolved in the observed populations, suggesting the outcomes were generally maintained through the duration of the OLE. However, long-term effects are not fully established under the rigorous, double-blind conditions of the initial trials.

Evidence gaps remain: comparative evidence is lacking for direct, head-to-head randomized trials against all currently approved biologic treatments across all indications. Evidence for children is limited. For the newest indication, ulcerative colitis, data are still emerging, and certainty remains low for outcomes beyond the one-year maintenance phase. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond.

Key Studies & References

1. Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients (COMMAND Maintenance Study)

Common questions about Skyrizi (FAQ)

---

Q: How long after my last dose of Skyrizi is it safe to get pregnant?

Official product information advises that the use of Skyrizi is generally not recommended during pregnancy due to limited data. Official guidance suggests that women who can become pregnant should use effective contraception during treatment and for a period of at least 21 weeks after the last dose. This time frame is based on the drug's half-life.

Q: Can I travel with Skyrizi, and how do I pack it?

Regulatory instructions detail specific storage conditions: Skyrizi must be kept refrigerated between 2 C and 8 C and protected from light. If a prefilled pen or syringe is removed from refrigeration, it must remain below 25 C (or 77 F) for a limited time, which is typically up to 14 days, though you should check the label for exact regional guidance. It is important that these temperature requirements are maintained during transit.

Q: What happens if I miss a dose of Skyrizi?

According to the official dosing guidelines, if you miss a subcutaneous maintenance dose of Skyrizi, the official guidelines state that a missed dose should be administered as soon as possible. Once the missed dose is taken, you should then return to your original treatment schedule.

Q: Can I get a flu shot or other non-live vaccine while on treatment?

Regulatory sources state that the co-administration of live vaccines is prohibited during treatment with Skyrizi. While the labeling does not contain a specific contraindication for non-live (inactivated) vaccines, it is advised that all age-appropriate vaccinations should be completed before you begin your treatment.

Q: Can I use Skyrizi if I have a history of cancer?

The drug's official safety documents do not list a history of cancer as an absolute reason to avoid the medication. The label advises against starting treatment in the presence of a clinically important active infection, such as active tuberculosis. Regulatory information does not provide specific guidance regarding use in patients with a history of cancer.

Q: Does Skyrizi cause hair loss or weight gain?

The official product safety profile, which classifies common side effects, does not list hair loss or weight gain among the most frequently reported adverse reactions. However, some changes, such as unexplained weight loss, may be a sign of a serious infection, which is a potential serious risk noted in safety documents.

Q: Are there any foods or dietary supplements I need to avoid while on Skyrizi?

Official regulatory information suggests that no clinically relevant interactions are expected between Skyrizi and other medicines (including supplements) that are processed through the body's main drug-metabolizing enzymes. The product information focuses primarily on drug interactions, such as those with vaccines.

Q: Is Skyrizi a chemotherapy drug?

No, Skyrizi is not classified as a chemotherapy drug. According to regulatory documents, the active ingredient, risankizumab-rzaa, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. It is classified as an Interleukin-23 (IL-23) antagonist used to target specific inflammatory pathways.

Q: How quickly does Skyrizi start working for my plaque psoriasis?

Studies and official information indicate that for plaque psoriasis, some patients may begin to see an improvement in their symptoms as early as Week 4 of treatment. A significant clinical response (e.g., a major reduction in disease severity) was achieved by many participants by the Week 16 analysis point in clinical trials.

How to Store and Dispose of Skyrizi

Skyrizi (risankizumab) requires specific handling and storage conditions to maintain its effectiveness. It must be stored in the refrigerator, protected from light, and should never be frozen or shaken.

Storage Requirement	Rule
Temperature	Store refrigerated between 2 C and 8 C (36 F and 46 F). Do not freeze.
Protection	Keep in the original carton to protect from light.
Handling	Do not shake. Visually inspect for discoloration or particles before use.

If the pre-filled pen or syringe is removed from the refrigerator, it should be allowed to warm naturally to room temperature before injection. Do not use external heat sources. After use, the device must be disposed of immediately in an FDA-cleared sharps disposal container. Keep all medication and sharps containers out of the reach of children.